No­var­tis li­cens­es Ky­orin’s pre­clin­i­cal chron­ic hives can­di­date for $55M up­front

No­var­tis is spend­ing $55 mil­lion on glob­al rights to Ky­orin Phar­ma­ceu­ti­cal’s pre­clin­i­cal drug for in­flam­ma­to­ry dis­eases in a deal that comes al­most two decades af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER